232 related articles for article (PubMed ID: 19204418)
21. What Do Placebo and Nocebo Effects Have to Do With Health Equity? The Hidden Toll of Nocebo Effects on Racial and Ethnic Minority Patients in Clinical Care.
Yetman HE; Cox N; Adler SR; Hall KT; Stone VE
Front Psychol; 2021; 12():788230. PubMed ID: 35002881
[TBL] [Abstract][Full Text] [Related]
22. Can pharmacogenetics help rescue drugs withdrawn from the market?
Shah RR
Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic application in drug development and clinical trials.
Shi MM; Bleavins MR; de la Iglesia FA
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):591-5. PubMed ID: 11259358
[TBL] [Abstract][Full Text] [Related]
24. Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.
Haga SB; Mills R; Bosworth H
Patient Educ Couns; 2014 Oct; 97(1):10-5. PubMed ID: 24985359
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
26. Trick or treat: the effect of placebo on the power of pharmacogenetic association studies.
Singer C; Grossman I; Avidan N; Beckmann JS; Pe'er I
Hum Genomics; 2005 Mar; 2(1):28-38. PubMed ID: 15814066
[TBL] [Abstract][Full Text] [Related]
27. Drug Response Pharmacogenetics for 200,000 UK Biobank Participants.
McInnes G; Altman RB
Pac Symp Biocomput; 2021; 26():184-195. PubMed ID: 33691016
[TBL] [Abstract][Full Text] [Related]
28. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy.
Katz DA; Murray B; Bhathena A; Sahelijo L
Nat Rev Drug Discov; 2008 Apr; 7(4):293-305. PubMed ID: 18382463
[TBL] [Abstract][Full Text] [Related]
29. Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice.
Schedlowski M; Enck P; Rief W; Bingel U
Pharmacol Rev; 2015 Jul; 67(3):697-730. PubMed ID: 26126649
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetic challenges for the health care system.
Robertson JA; Brody B; Buchanan A; Kahn J; McPherson E
Health Aff (Millwood); 2002; 21(4):155-67. PubMed ID: 12117126
[TBL] [Abstract][Full Text] [Related]
31. The nocebo effect as a source of bias in the assessment of treatment effects.
Wartolowska K
F1000Res; 2019; 8():5. PubMed ID: 31354941
[TBL] [Abstract][Full Text] [Related]
32. Context as a drug: some consequences of placebo research for primary care.
Lucassen P; Olesen F
Scand J Prim Health Care; 2016 Dec; 34(4):428-433. PubMed ID: 27978780
[TBL] [Abstract][Full Text] [Related]
33. Physicians' opinions following pharmacogenetic testing for psychotropic medication.
Walden LM; Brandl EJ; Changasi A; Sturgess JE; Soibel A; Notario JF; Cheema S; Braganza N; Marshe VS; Freeman N; Tiwari AK; Kennedy JL; Müller DJ
Psychiatry Res; 2015 Oct; 229(3):913-8. PubMed ID: 26298505
[TBL] [Abstract][Full Text] [Related]
34. Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.
Chang WC; Tanoshima R; Ross CJD; Carleton BC
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():65-84. PubMed ID: 33006916
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetic testing, informed consent and the problem of secondary information.
Netzer C; Biller-Andorno N
Bioethics; 2004 Aug; 18(4):344-60. PubMed ID: 15449406
[TBL] [Abstract][Full Text] [Related]
36. [Placebo and nocebo effects on itch : Methodological and clinical implications].
Tekampe J; Peerdeman KJ; Bartels DJP; van Laarhoven AIM; Evers AWM
Hautarzt; 2018 Aug; 69(8):626-630. PubMed ID: 29947820
[TBL] [Abstract][Full Text] [Related]
37. Consent and privacy in pharmacogenetic testing.
Robertson JA
Nat Genet; 2001 Jul; 28(3):207-9. PubMed ID: 11431685
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic mechanisms underlying unanticipated drug responses.
Carlquist JF; Anderson JL
Discov Med; 2011 May; 11(60):469-78. PubMed ID: 21616045
[TBL] [Abstract][Full Text] [Related]
39. [The role of placebo and nocebo mechanisms in depressive diseases and their treatment].
Rief W
Nervenarzt; 2020 Aug; 91(8):675-683. PubMed ID: 32607602
[TBL] [Abstract][Full Text] [Related]
40. An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.
Oni-Orisan A; Tuteja S; Hoffecker G; Smith DM; Castrichini M; Crews KR; Murphy WA; Nguyen NHK; Huang Y; Lteif C; Friede KA; Tantisira K; Aminkeng F; Voora D; Cavallari LH; Whirl-Carrillo M; Duarte JD; Luzum JA;
Clin Pharmacol Ther; 2023 Aug; 114(2):275-287. PubMed ID: 37303270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
